1. Bild D, Teutsch SM. The control of hypertension in persons with diabetes: a public health approach. Public Health Rep. 1987; 102:522-9.

2. Sowers JR. Treatment of hypertension in patients with diabetes. Arch Intern Med. 2004; 164: 1850-1857.

3. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.

4. Clermont A, Bursell SE, Feener EP. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J Hypertens Suppl. 2006; 24: S73-80.

5. Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension 2006; 48:519-526.

6. Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study Hypertension 2006; 47:410-4.

7. Equiluz-Bruck S, Schnack C, Kopp HP, et al. Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type-2 diabetes mellitus. Am J Hypertension 1996; 9:1139-43.

8. Poulsen PL, Beck T, Ebbehoi E, et al. 24h ambulatory blood pressure and retinopathy in normoalbuminuric IDDM patients. Diabetologia 1998; 41:105-10.

9. Farmer CK, Goldsmith DJ, Quin JD, et al. Progression of diabetic nephropathy-is diurnal blood pressure rhythm as important as absolute blood pressure level? Nephrol Dial Transplant. 1998; 13: 635-9.

10. Chen JW, Jen SL, Lee WL, et al. Differential glucose tolerance in dipper and nondipper essential hypertension. Diabetes Care 1998; 21:1743-1748.

11. Nakano S, Fukuda M, Hotta F, et al: Reversed circadian blood pressure rhythm is associated with occurences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 1998; 47:1501-6.

12. Schernthaner G, Ritz E, Philipp T, et al. Night time blood pressure in diabetic patients - the submerged portion of the iceberg? Nephrol.Dial Transplant 1999; 14:1061-1064.

13. Andersen Ar, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983; 25:496-501.

14. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. Br Med J. 1987; 295:575-577.

15. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-33.

16. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-81.

17. DeFronzo RA, Ferrannini E: Insulin resistance - a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atheroslerotic disease. Diabetes Care 1991; 14:173-94.

18. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: N Engl J Med 2000; 342:905-12.

19. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based Antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276:1886-92.

20. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complication in type-2 diabetes: UKPDS 38. BMJ 1998; 317:703-13.

21. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type-2 diabetes: UKPDS 39. BMJ 1998; 317:713-20.

22. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351:1755-62.

23. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340:677-84.

24. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-16.

25. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.

26. Svensson P, de Faire U, Sleight Pz, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38:E28-32.

27. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356:366-72.

28. Hansson L, Hedner T, Lund-Johanson P, et al. Randomized trial of effects of calcium-antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study. Lancet 2000; 356:359-65.

29. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.

30. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-10.

31. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18:1671-75.

32. Adler AI, Stratton M, Neil HAW, et al. Association of systolic blood pressure with macrovascular complications of type-2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-9.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihyper-tensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethia-zide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2002; 366:895-906. The Hypertension Detection and Follow-up Programme Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up programme, stratified by other risk factors. Prev Med 1985; 14:312-35.

Yusuf S, Sleight P, Pogue J, et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.

Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.

Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-52.

Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/ beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24:2091-6.

Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or Co-Amizolide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 2003; 41:431-6.

Yoon KH, Lee JH, Kim JW et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-8.

United State Renal Data System. 2005 Annual data report; atlas of end-stage renal disease in the United States. Bethesda, MD, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.

Schernthaner G. Kidney disease in Diabetology. Nephrol Dial Transplant. 2007; 22:703-7. Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289:3273-7. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27:195-200.

Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.

Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 2001; 345:870-8. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005; 16:2170-9. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005; 16:3027-37. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol. 2007; 18:1540-6.

Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55:3550-5.

Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351:1952-61.

Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. Bergamo

Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. N Engl J Med. 2004; 351:

Weight Loss Enigma

Weight Loss Enigma

Finally Revealed The Revolutionary & Miraculous Weight Loss Secrets! Discover How to Command Those Unwanted Pounds To Take A Hike, So That You Can Get Into Shape & Lose Weight Easily Just Like You Dream Of In Just A Matter Of Weeks! You're About to Discover The Insider's Fat Burning Diet Tips to Easily Shed Off Those Extra Pounds And Obtain a Lovable Shape In No Time Flat!

Get My Free Ebook

Post a comment